Table 2.

Representative clinical trials evaluating the combination of PD-1/PD-L1 blockade immunotherapy and conventional chemotherapy in EGFR-mutant NSCLC patients.

Clinical trial #	PD-1/PD-L1 blockade therapy	Chemotherapy	Key findings	Reference
PACIFIC	Durvalumab (PD-L1 antibody)	Platinum-based chemotherapy	- Phase III trial evaluating durvalumab as consolidation therapy in stage III NSCLC patients who did not present disease progression after 2 or more cycles of chemotherapy. - In patient subgroup analysis, patients with EGFR mutations demonstrated slightly more clinical benefit from durvalumab after chemoradiotherapy.	(51)
Checkmate 722 (NCT02864251)	Nivolumab (PD-1 antibody)	Pemetrexed, cisplatin, or carboplatin	- Open-label phase III trial enrolling ~500 patients with confirmed stage IV or recurrent EGFR mutated NSCLC progressed on prior EGFR TKI therapy - Efficacy of nivolumab plus chemotherapy, nivolumab plus ipilimumab and chemotherapy alone was compared. - Final result has not been reported.	(117)
KEYNOTE-789 (NCT03515837)	Pembrolizumab (PD-1 antibody)	Pemetrexed, carboplatin or cisplatin	- Ongoing Phase II trial which compared efficacy of pembrolizumab and its combination with chemotherapy - It also recruited NSCLC patients bearing EGFR T790M who have acquired resistance to osimertinib	(118)